3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
2
Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
Doxorubicin
33
Ifosfamide
23
Gemcitabine
19
pazopanib
18
Cyclophosphamide
16
Radiotherapy
15
pembrolizumab
13
Filgrastim
12
Docetaxel
12
Bevacizumab
10
Vincristine
9
Sirolimus
9
Irinotecan
9
Etoposide
9
olaratumab
7
eribulin
7
Sorafenib
7
Radiation
7
temsirolimus
6
Temozolomide
6
Mesna
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
tazemetostat
5
cixutumumab
5
Trabectedin
5
Radiosurgery
5
Nivolumab
5
Ipilimumab
5
Granulocyte Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Sarcoma
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts